Empitical therapy with cefoperazone was compared with cefoperazone plus amikacin in granulocytopenic and nongranulocytopenic febrile patients. In nonneutropenic patients the overall response rate to cefoperazone was 88%; 10 of 12 gram-negative bacteremic patients were cured. Cefoperazone plus amikacin resulted in an 88% overall response rate and cured 14 of 15 patients with bacteremia. In neutropenic patients the overall response rate was 77% with cefoperazone alone and 73% with cefoperazone plus amikacin; the cure rates for gram-negative bacteremias were 8 of 11 and 6 of 12 patientsj,espectively. Infection in cancer patients can rapidly become a lifethreatening situation, especially in the presence of gram-negative bacteremia and bone marrow failure (12). When sepsis is suspected, usually on the basis of fever, prompt antimicrobial therapy and adequate supportive care are needed before the nature and susceptibility of the pathogens are known. Empirical therapy should provide adequate coverage against all the likely pathogens. Gram-negative bacilli are the most common pathogens in severe infections of the immunocompromised host, especially neutropenic patients, and infection may be rapidly fatal under these conditions. Until now, a broad-spectrum activity could only be achieved with combinations of antimicrobial agents, namely, beta-lactam antibiotics and aminoglycosides; these combinations, which frequently have a synergistic action against members of the family Enterobacteriacae and Pseudomonas aeruginosa, have been shown to be associated with a better clinical outcome than single-drug therapy (6). However, antibiotic combination therapy is associated with an increased frequency of allergic and toxic reactions, a potentially difficult situation in cancer patients who are already exposed to the toxicity of their anti-cancer treatment.
Empitical therapy with cefoperazone was compared with cefoperazone plus amikacin in granulocytopenic and nongranulocytopenic febrile patients. In nonneutropenic patients the overall response rate to cefoperazone was 88%; 10 of 12 gram-negative bacteremic patients were cured. Cefoperazone plus amikacin resulted in an 88% overall response rate and cured 14 of 15 patients with bacteremia. In neutropenic patients the overall response rate was 77% with cefoperazone alone and 73% with cefoperazone plus amikacin; the cure rates for gram-negative bacteremias were 8 of 11 and 6 of 12 patientsj,espectively. Our Infection in cancer patients can rapidly become a lifethreatening situation, especially in the presence of gram-negative bacteremia and bone marrow failure (12) . When sepsis is suspected, usually on the basis of fever, prompt antimicrobial therapy and adequate supportive care are needed before the nature and susceptibility of the pathogens are known. Empirical therapy should provide adequate coverage against all the likely pathogens. Gram-negative bacilli are the most common pathogens in severe infections of the immunocompromised host, especially neutropenic patients, and infection may be rapidly fatal under these conditions. Until now, a broad-spectrum activity could only be achieved with combinations of antimicrobial agents, namely, beta-lactam antibiotics and aminoglycosides; these combinations, which frequently have a synergistic action against members of the family Enterobacteriacae and Pseudomonas aeruginosa, have been shown to be associated with a better clinical outcome than single-drug therapy (6) . However, antibiotic combination therapy is associated with an increased frequency of allergic and toxic reactions, a potentially difficult situation in cancer patients who are already exposed to the toxicity of their anti-cancer treatment. This is why the possibility of using a single drug for empirical therapy in febrile cancer patients appears appealing, provided a broad antimicrobial spectrum and an adequate bactericidal activity can be obtained. The introduction of the so-called "third-generation cephalosporins" offers a possibility for single-drug therapy in immunocompromised patients.
The preliminary results of empirical therapy with the latest cephalosporins are encouraging (4); however, no final statement can be made at the present time as to whether this empirical monotherapy is more or less active than the aminoglycoside-containing combinations.
Cefoperazone is a cephalosporin of the third generation. It has low minimal inhibitory and bactericidal concentrations against most aerobic gram-negative bacilli and a satisfactory * Corresponding author. activity against anaerobes (with the exception of Bacteroides fragilis) and Staphylococcus aureus. Its pharmacological properties and therapeutic effectiveness have recently been reviewed (2) .
We conducted a prospective randomized study to compare empirical therapy with cefoperazone alone with empirical therapy with cefoperazone plus amikacin in cancer patients, whether neutropenic or nonneutropenic. The purpose of the study was to compare the clinical and the bacteriological effectiveness of these two forms of empirical therapy and to analyze the results with regard to the emergence of cefoperazone-resistant strains and the level of bactericidal activity in the serum.
MATERIALS AND METHODS
Nongranulocytopenic cancer patients with presumed bacteremia and neutropenic febrile patients (less than 1,000 neutrophils per ,ul; temperature greater than 38.5°C) were eligible for the study.
Patients were randomly assigned to receive intravenously either 6 g of cefoperazone twice daily (BID) or 2 g of cefoperazone plus 500 mg of amikacin BID. The antibiotics were administered simultaneously. These regimens were chosen on the basis of our own studies that demonstrated identical bactericidal activities against common gram-negative bacilli of the serum of volunteers who had a high dose of cefoperazone (6 g BID) and the serum of volunteers who had a combination of a lower dose of cefoperazone (2 g BID) and amikacin (500 mg BID) (11) . Antibiotics were dissolved in 150 ml of 5% dextrose in water and were infused over 15 min.
After informed consent and before the onset of antibiotic treatment, specimens for culture were If a gram-positive infection was microbiologically documented, therapy was adjusted to the in vitro susceptibility of the pathogen, and the case was excluded from further evaluation.
"Superinfection" was defined as an infection caused by a different organism that occurred during or after treatment and required a change of therapy. In that case, the result of empirical therapy might have been considered as a success, but the actual outcome of the infectious episode was a failure.
RESULTS
A total of 49 neutropenic patients and 105 nonneutropenic patients were randomly assigned to one of the two treatment regimens. The results in gram-negative bacteremia deserve special consideration. Cefoperazone was effective in 18 of 23 (78%) of these episodes (8 of 11 neutropenic patients), and cefoperazone plus amikacin was successful in 22 of 27 (81%) of these episodes (8 of 12 neutropenic patients). The distribution of these bacteremias by organism is presented in Table  3 .
Among nonneutropenic patients with gram-negative bacteremia, there were only three failures, whose characteristics are outlined in Table 4 . The infecting organisms responsible for these infections were resistant in vitro to cefoperazone; the serum bactericidal activity (SBA) was relatively low in two patients and was difficult to interpret in the other patient, who was infected with a serum-susceptible strain.
Among the neutropenic patients, there was an equal distribution between the two treatment arms of prognostic factors such as underlying diseases, known or unknown site of infection, and initial granulocyte count ( Table 5 ). The response rate was six of eight and five of seven for severely neutropenic patients (<100 granulocytes per ,1l) with gramnegative bacillary bacteremia who were treated with cefoperazone and cefoperazone plus amikacin, respectively. Over- all, seven failures were encountered (Table 6 ): three in the cefoperazone arm and four in the cefoperazone plus amikacin arm. Of these seven patients with bacteremia who failed to respond to empirical therapy, three had polymicrobial bacteremia, four had severe granulocytopenia (<100 neutrophils per p.l), and P. aeruginosa was isolated from the blood in five. Only two P. aeruginosa strains (one in each arm) were resistant in vitro to cefoperazone, but these two infections were not fatal; all the other gram-negative strains were susceptible in vitro to both cefoperazone and amikacin. The SBA, as determined 1 h after the administration of the antibiotics, was available for four granulocytopenic patients who failed to respond; it was at least 1:16 in the two cefoperazone-treated patients. Nevertheless, one of them died in septic shock. In the two patients who received cefoperazone plus amikacin and failed to respond, the serum bactericidal titer was 1:8; both patients survived after adjustment of antimicrobial therapy.
The median values of the serum bactericidal titers observed in our study in patients with gram-negative bacillary bacteremia are shown in Table 7 . The figures were not different for patients who received cefoperazone and those who received cefoperazone plus amikacin but were high (1:128 to 1:512) with both regimens. As already mentioned, the SBA was lower in patients who failed to respond than in the others. Superinfection occurred more frequently in the patients specifically, diarrhea was not observed, although it might who received cefoperazone plus amikacin (Table 8) . Overall, have been feared with 6 g of cefoperazone BID. cefoperazone was associated with superinfection in 4 of 80 (5%) patients, whereas the corresponding figure for cefoper-DISCUSSION azone plus amikacin was 9 of 74 (12%) patients. However, the difference is not statistically significant. Similarly, no
The present study indicates that cefoperazone is an effecsignificant difference between neutropenic and nonneutropetive and safe empirical therapy for cancer patients suspected nic patients could be detected; the overall rate of superinof having gram-negative bacillary sepsis, whatever their fection was 4 of 49 (8.2%) and 9 of 105 (8.5%) patients, granulocyte count is. In nonneutropenic patients, we obrespectively.
served an overall response rate to cefoperazone monotherBoth regimens were well tolerated; besides superinfecapy of 88%; 10 of 12 (83%) bacteremic patients were cured. tion, no side effects that could be clearly related to the These results confirm previously reported studies from our administration of the study regimens were noted. More hospital on the effectiveness of cefoperazone monother- apy-even at a lower dosage-in cancer patients with gramnegative bacteremia and normal granulocyte counts (7) .
However, these conclusions about therapeutic equivalence must be tempered because of the preponderance in our series of the more susceptible gram-negative pathogens. Certainly, when Escherichia coli and Klebsiella infections predominate, monotherapy might well be successful even in the granulocytopenic patients. However, there is still need for improvement in treating polymicrobial sepsis, particularly when it involves Pseudomonas spp. The combination of cefoperazone plus amikacin gave similar results in nonneutropenic patients, with an overall response rate of 88% and 14 cures in 15 (93%) patients with gram-negative bacteremia.
Likewise, among the 49 febrile neutropenic patients in this study, no difference in the clinical outcome could be detected between those treated with cefoperazone alone and those treated with cefoperazone plus amikacin; 77 and 73% of the patients, respectively, responded to empirical therapy with cefoperazone and cefoperazone plus amikacin; a definite cure was obtained in 8 of 11 and 6 of 12 patients, respectively, with gram-negative bacteremia.
Data on the use of the newest cephalosporins for empirical therapy in granulocytopenic patients are still fragmentary at the present time. Ceftazidime alone was investigated in several studies (4), with encouraging results, even in P. aeruginosa infection. With an overall response rate of 77% in this study, cefoperazone monotherapy also appears to be effective in neutropenic patients, but there were only three P. aeruginosa infections in our series, and one failed to respond. However, in a previous study, cefoperazone was found to be very active in cancer patients with gram-negative bacteremia (7) .
Thus far, we have been unable to detect a difference in the responses of nonneutropenic and neutropenic patients to a high dose of cefoperazone or to the combination of lowerdosage cefoperazone plus amikacin given as empirical therapy for suspected sepsis; other studies failed to document a favorable effect of synergism on the outcome with nonneutropenic patients (1) . However, in neutropenic patients, synergistic combinations capable of achieving high SBAs are regularly associated with improved clinical efficacy as compared with single-drug treatment or the use of nonsynergistic combinations (6) .
In this study, as could be predicted from previous studies in our laboratory (10) , cefoperazone alone resulted in a high SBA against pathogens which all were susceptible in vitro. It is possible that synergy is only one of several possible ways to produce a high bactericidal activity in the blood and that, in fact, the actual SBA level is the major factor responsible for the outcome in cases of gram-negative bacteremia (5, 9) .
Only a few studies comparing, prospectively, a new cephalosporin to the same drug combined with an aminoglycoside are available, and preliminary data have been reported so far (4). Although these investigations do not suggest a superiority of the combinations over single-drug therapy, no definite statement can be made at the present time as to whether empirical monotherapy with cefoperazone or another new cephalosporin with adequate antiPseudomonas activity will be more or less successful than the conventional treatment with aminoglycoside-containing combinations.
High doses of antibiotics might be especially useful to treat deep-tissue infection, where aminoglycosides and beta-lactams, when given in relatively low doses, have suboptimal penetration.
Our recent studies of the SBAs of volunteers receiving new cephalosporins, such as cefoperazone or ceftazidime, with or without amikacin have shown satisfactory activity of these drugs against P. aeruginosa 4nd most members of the family Enterobacteriaceae (11); cefoperazone and ceftazidime alone were as active as the combination of cefoperazone or ceftazidime with amikacin. However, the rate of killing was greater with the combinations as compared with cefoperazone or ceftazidime alone. Whether the rate of killing will prove to be clinically significant remains to be seen; at the present time, the actual value of the peak SBA appears to be a sufficiently accurate predictive test per se (5, 9).
Nevertheless, even if the SBA is useful to predict the clinical outcome, it does not necessarily provide an explanation for all the failures of antibiotic therapy; although we found that bacteremic patients who failed to respond had lower SBAs as compared with the median value for the entire group, in at least two cases, the SBA was theoretically adequate (-1:16). Besides the SBA, which reflects both the susceptibility of the pathogen and the levels of antimicrobial drugs achieved in the blood, the overwhelming importance of host factors, such as the effectiveness of phagocytic cells, the integrity of the anatomical barriers against the spread of infection, and probably many others, which all affect the outcome of any infectious process, should be reemphasized here: in our patients, the severity of the underlying disease, profound granulocytopenia, the presence of infectious sites not accessible to drainage, and P. aeruginosa and polymicrobial bacteremia were all poor prognostic factors, which may have accounted for the clinical failures in spite of adequate antimicrobial therapy as reflected by adequate SBAs.
The present favorable clinical situation with new cephalosporins, such as cefoperazone, might be related to the relatively rare occurrence of resistant strains. However, the emergence of cephalosporin-resistant strains has already been observed in several other clinical studies (8 failure to respond to cefoperazone or cefoperazone plus amikacin. One of these patients died, one improved after the addition of amikacin to cefoperazone, and three others improved only when an active cephalosporin (ceftazidime) was substituted for cefoperazone. There were three superinfections with resistant strains (one Klebsiella pneumoniae and two Pseudomonas cepacia strains).
In conclusion, our study supports to some extent the concept of single-drug empirical therapy with the newest cephalosporins for suspected gram-negative bacillary sepsis in cancer patients. In all patients with gram-positive-organism bacteremias, therapy could be safely adjusted when the nature and susceptibility of the offending pathogen were established. However, our conclusions might only apply for the time being, when resistance of gram-negative bacilli to these agents is relatively rare, and should be revised if the present favorable situation should change.
